A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors

NCT07380334 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: SHR-1049 Injection

Sponsor

Jiangsu HengRui Medicine Co., Ltd.